The Trump administration recently implemented new tariffs on branded pharmaceutical drugs from companies that have not finalized agreements to reduce U.S. drug prices. This measure, an administration official stated, aims to enhance the security and domestic production of the nation’s drug supply.
Patented medications and their active ingredients will face a 100% tariff under the new plan. Drug manufacturers, however, have avenues to mitigate or avoid these levies. A 20% tariff applies to companies committing to onshore production, though this rate will increase to 100% after four years. Firms with executed drug pricing deals or those actively negotiating with the Health and Human Services Department while establishing domestic manufacturing (new U.S. plants by January 2029) will be exempt.
Larger pharmaceutical firms have 120 days before the 100% tariff takes effect, while smaller drugmakers have 180 days. Internationally, countries with broader trade agreements with the U.S. will incur different rates; the European Union, Japan, Korea, and Switzerland will face a 15% tariff, and the United Kingdom a 10% tariff, partly due to its government’s increase in pharmaceutical purchasing prices.
Generic products, biosimilars, and related ingredients are currently exempt, with a review scheduled in one year. Certain specialty pharmaceutical items, including those for animal health and rare conditions, will also be exempt if sourced from trade deal countries or if they address an urgent public health need. This action follows a Commerce Department investigation that identified certain pharmaceutical imports as a national security risk.
In a separate move, the administration revised tariffs on imported raw materials like steel, aluminum, and copper, and products containing these metals. The 50% duty on raw materials will now apply to the full price paid by U.S. importers, aimed at preventing undervaluation. Finished products with over 15% of these metals will face a 25% tariff on their total value, while those with less than 15% metal content will not be subject to new duties. Although the administration foresees no impact on goods costs, non-governmental analyses project a modest increase in the effective duty rate.
Source: Original
